Morningstar

Opus Genetics Inc Ordinary Shares IRD

Stock XNAS Rating as of Oct 16, 2026

News

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

GlobeNewswire Oct 16, 2026, 4:00:00 PM
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

GlobeNewswire Oct 15, 2026, 8:00:00 PM
Opus Genetics to Present at the Chardan Annual Healthcare Conference

GlobeNewswire Oct 13, 2026, 11:00:00 AM
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

GlobeNewswire Sep 9, 2026, 11:00:00 AM
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

GlobeNewswire Sep 2, 2026, 11:00:00 AM
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

GlobeNewswire Aug 19, 2026, 8:05:00 PM
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Aug 19, 2026, 8:01:00 PM
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

GlobeNewswire Aug 6, 2026, 11:00:00 AM
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

GlobeNewswire Aug 3, 2026, 11:00:00 AM
Opus Genetics Gene Therapy Accepted into FDA's Rare Disease Program

Global News Select May 4, 2026, 9:57:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.